戻る
Prokidney Corp (PROK)価格
PROK 株価推移チャート
PROK 収入
Prokidney Corp
$2.29
5.04%
$0.1
終値： Jan 16, 16:00:00 GMT-5
$2.24
-2.18%
$-0.04
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$2.18
始値
$2.21
当日レンジ
$2.16 - $2.31
52週レンジ
$0.46 - $7.13
取引高
1.5M
平均取引高
1.3M
1株当たり利益(TTM)
-0.54
配当利回り
--
時価総額
$673.8M
PROKとは何ですか？
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.